Selecting the optimal treatment for glucocorticoid-induced osteoporosis

Joint Bone Spine

Volumn 78, Issue , 2011, Pages S218-S221

  Chopin, Florence ^a   Hoppé, Emmanuel ^b   Morel, Gauthier ^c   Biver, Emmanuel ^d   Borg, Séverine ^e   Thomas, Thierry ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c CENTRE HOSPITALIER   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CHU PURPAN   (France)

Author keywords

Bisphosphonate; Calcium; Glucocorticoid induced osteoporosis; Teriparatide; Treatment; Vitamin D

Indexed keywords

ANTIINFLAMMATORY AGENT; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; EDITORIAL; FEMALE; FRAGILITY FRACTURE; HUMAN; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIETARY SUPPLEMENTS; FEMALE; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS;

MLCS; MLOWN;

EID: 84860247679     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/S1297-319X(11)70009-4     Document Type: Article

References (22)

1. Orcel, P., Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine 72 (2005), 461–465.
2. Van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al. Use of oral corticosteroids in the United Kingdom. QJM 93 (2000), 105–111.
3. Lafage-Proust, M.H., Boudignon, B., Thomas, T., Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 70 (2003), 109–118.
4. Van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al. use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 (2000), 993–1000.
5. Curtis, J.R., Westfall, A.O., Allison, J.J., et al. longitudinal patterns in the prevention of osteoporosis in glucocorticoids treated patients. Arthritis Rheum 52 (2005), 2485–2494.
6. Lespessailles, E., Cotté, F.E., Roux, C., et al. Prevalence and features of osteoporosis in the French general population: The Instant study. Joint Bone Spine 76 (2009), 394–400.
7. Guggenbuhl, P., Osteoporosis in males and females: Is there really a difference?. Joint Bone Spine 76 (2009), 595–601.
8. Briot, K., Cortet, B., Trémollières, F., et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine 76 (2009), 129–133.
9. Roux, C., Confavreux, C.B., Cortet, B., et al. Severe osteoporosis: diagnosis and follow-up. Lessons for clinical practice. Joint Bone Spine 77 (2010), S139–S141.
10. Richy, F., Ethgen, O., Bruyere, O., et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15 (2004), 301–310.
11. Amin, S., LaValley, M.P., Simms, R.W., et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42 (1999), 1740–1751.
12. Adachi, J.D., Bensen, W.G., Brown, J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 (1997), 382–387.
13. Roux, C., Oriente, P., Laan, R., et al., Ciblos Study Group. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83 (1998), 1128–1133.
14. Adachi, J.D., Saag, K.G., Delmas, P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 (2001), 202–211.
15. Lems, W.F., Lodder, M.C., Lips, P., et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebocontrolled trial. Osteoporos Int 17 (2006), 716–723.
16. Cohen, S., Levy, R.M., Keller, M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999), 2309–2318.
17. Reid, D.M., Hughes, R.A., Laan, R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15 (2000), 1006–1013.
18. Wallach, S., Cohen, S., Reid, D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67 (2000), 277–285.
19. Homik, J., Cranney, A., Shea, B., et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev, 2, 2000, CD001347.
20. Reid, D.M., Devogelaer, J.P., Saag, K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373 (2009), 1253–1263.
21. Saag, K.G., Shane, E., Boonen, S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Eng J Med 357 (2007), 2028–2039.
22. Langdahl, B.L., Marin, F., Shane, E., et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20 (2009), 2095–2104.